Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Achieve Life Sciences (ACHV) today and set a price target of $10.00. The company’s shares closed last Monday at $0.31, close to its 52-week low of $0.30.
According to TipRanks.com, Higgins has currently no stars on a ranking scale of 0-5 stars, with an average return of -20.2% and a 23.2% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Zynerba Pharmaceuticals, and Rhythm Pharmaceuticals.
Achieve Life Sciences has an analyst consensus of Moderate Buy, with a price target consensus of $2.00.
The company has a one-year high of $4.63 and a one-year low of $0.30. Currently, Achieve Life Sciences has an average volume of 2.54M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of cytisinicline for smoking cessation. Its products includes cytisine, a plant-based alkaloid with a binding affinity to the nicotinic acetylcholine receptor.